LEXARIA BIOS.CORP.DL-,001 Aktie

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization ("CRO") to begin to implement and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).» Mehr auf accesswire.com

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®. The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.» Mehr auf accesswire.com

H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as planned. The GLP-1-H24-4 study includes four planed DehydraTECH formulation arms and one Rybelsus comparator control arm and is slated to enroll 20 20 overweight, obese, pre- or type 2 diabetic patients for each of arms 1-4 at seven clinical sites, with the DehydraTECH-tirzepatide Arm 5 to be added at a later date if supported by positive results from the separate ongoing study GLP-1- H24-3, the analyst tells investors in a research note. Positive results from this study could expand the application of the DehydraTECH delivery technology in the GLP-1 sector, the firm says.» Mehr auf thefly.com